Zynex Inc. (OTCMKTS:ZYXI) released its quarterly earnings results on Monday. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01, Bloomberg Earnings reports. Zynex had a negative return on equity of 86.24% and a net margin of 18.12%.
Shares of Zynex (OTCMKTS ZYXI) traded up $0.07 during mid-day trading on Tuesday, hitting $3.07. The company’s stock had a trading volume of 7,918 shares, compared to its average volume of 38,493. Zynex has a one year low of $0.10 and a one year high of $2.94. The stock has a market cap of $91.66, a P/E ratio of 35.75 and a beta of -0.03. The company has a quick ratio of 0.60, a current ratio of 0.64 and a debt-to-equity ratio of -0.04.
A number of research firms recently issued reports on ZYXI. Taglich Brothers restated a “speculative buy” rating on shares of Zynex in a research note on Monday, August 21st. ValuEngine upgraded Zynex from a “hold” rating to a “buy” rating in a research note on Wednesday, August 23rd.
WARNING: This article was originally reported by Stock Observer and is owned by of Stock Observer. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.thestockobserver.com/2017/11/14/zynex-inc-zyxi-issues-quarterly-earnings-results.html.
Zynex, Inc operates through the Electrotherapy and Pain Management Products segment. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc (ZMI). Its other subsidiaries include Zynex Monitoring Solutions, Inc (ZMS) and Zynex Europe, ApS (ZEU). ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation.
Receive News & Ratings for Zynex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex Inc. and related companies with MarketBeat.com's FREE daily email newsletter.